Related Experiment Videos
Circulating intercellular adhesion molecule-1 in patients with lung cancer
O Taguchi1, E C Gabazza, T Kobayashi
1Third Department of Internal Medicine, Mie University School of Medicine.
Internal Medicine (Tokyo, Japan)
|January 1, 1997
Summary
Lung cancer patients show higher levels of intercellular adhesion molecule-1 (ICAM-1) in their blood compared to healthy individuals. ICAM-1 levels correlate with advanced lung cancer stages but are not significantly altered by chemotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Abnormal expression of adhesion molecules is linked to malignancy.
- Intercellular adhesion molecule-1 (ICAM-1) is implicated in tumor invasion and metastasis.
Purpose of the Study:
- To measure soluble ICAM-1 levels in lung cancer patients.
- To evaluate the impact of cytotoxic therapy on ICAM-1 levels.
Main Methods:
- Serum soluble ICAM-1 concentrations were measured using enzyme immunoassay.
- Measurements were taken before and during chemotherapy in 19 lung cancer patients.
- Data were compared with healthy volunteers.
Main Results:
- Soluble ICAM-1 serum concentration was significantly higher in lung cancer patients versus controls (p < 0.0001).
- Elevated ICAM-1 levels were more pronounced in advanced disease stages (p < 0.02).
- No significant change in ICAM-1 levels was observed after multidrug cytotoxic therapy.
Conclusions:
- Lung cancer is associated with increased circulating adhesion molecules like ICAM-1.
- ICAM-1 levels correlate with clinical stage in lung cancer.
- Cytotoxic therapy does not significantly affect circulating ICAM-1 levels in this cohort.